Compare · BSX vs CVRX
BSX vs CVRX
Side-by-side comparison of Boston Scientific Corporation (BSX) and CVRx Inc. (CVRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CVRX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 1727.4x CVRX ($37.0M).
- Over the past year, BSX is down 55.9% and CVRX is down 87.0% - BSX leads by 31.1 points.
- BSX has hit the wire 4 times in the past 4 weeks while CVRX has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 16 for CVRX).
- Company
- Boston Scientific Corporation
- CVRx Inc.
- Price
- $44.38+0.50%
- $1.31-5.42%
- Market cap
- $63.97B
- $37.0M
- 1M return
- +1.88%
- -56.48%
- 1Y return
- -55.85%
- -86.99%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 16
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest CVRX
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Appoints John Landry as Chief Financial Officer
- CVRx Responds to Letter from Pointillist Family Office
- Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
- CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
- CHIEF OPERATING OFFICER Binkowski Brent bought $76,432 worth of shares (26,223 units at $2.91), increasing direct ownership by 87% to 56,514 units (SEC Form 4)
- CHIEF OPERATING OFFICER Binkowski Brent sold $3,338 worth of shares (1,309 units at $2.55), decreasing direct ownership by 4% to 30,291 units (SEC Form 4) (tax liability)
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Sales Leadership Transition
- CVRx, Inc. downgraded by Craig Hallum with a new price target